FDA accepts Corcept's NDA for relacorilant in platinum-resistant ovarian cancer; PDUFA July 11, 2026

CORCEPT THERAPEUTICS INC

FDA accepted Corcept's NDA for relacorilant in platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.
NDA based on positive Phase 3 ROSELLA and Phase 2 data showing improved PFS and OS without biomarker selection.
Relacorilant plus nab-paclitaxel was well-tolerated; adverse events similar to nab-paclitaxel monotherapy.
CEO Joseph Belanoff: 'FDA acceptance brings us closer to offering a much-needed treatment option for this dire disease.'
Relacorilant may redefine platinum-resistant ovarian cancer treatment, Corcept states.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.